You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 25, 2024

~ Buy the ERAXIS (anidulafungin) Drug Profile, 2024 PDF Report in the Report Store ~

ERAXIS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Eraxis patents expire, and when can generic versions of Eraxis launch?

Eraxis is a drug marketed by Vicuron Holdings and is included in one NDA.

The generic ingredient in ERAXIS is anidulafungin. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the anidulafungin profile page.

Summary for ERAXIS
Drug patent expirations by year for ERAXIS
Drug Prices for ERAXIS

See drug prices for ERAXIS

Recent Clinical Trials for ERAXIS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Texas Southwestern Medical CenterPhase 4
National Center for Research Resources (NCRR)Phase 4
Texas Tech University Health Sciences CenterPhase 4

See all ERAXIS clinical trials

Pharmacology for ERAXIS

US Patents and Regulatory Information for ERAXIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ERAXIS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 ⤷  Sign Up ⤷  Sign Up
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 ⤷  Sign Up ⤷  Sign Up
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 ⤷  Sign Up ⤷  Sign Up
Vicuron Holdings ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for ERAXIS

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Pfizer Europe MA EEIG Ecalta anidulafungin EMEA/H/C/000788
Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years.
Authorised no no no 2007-09-20
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ERAXIS

See the table below for patents covering ERAXIS around the world.

Country Patent Number Title Estimated Expiration
Israel 105048 CYCLIC PEPTIDE ANTIFUNGAL AGENTS AND PROCESS FOR PREPARATION THEREOF ⤷  Sign Up
Japan 4936595 ⤷  Sign Up
European Patent Office 0561639 Dérivés cyclopeptidiques antifongiques et procédé de leur préparation (Cyclic peptide antifungal agents and process for preparation thereof) ⤷  Sign Up
Hungary T63637 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ERAXIS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0561639 SPC002/2008 Ireland ⤷  Sign Up SPC002/2008: 20081105, EXPIRES: 20180317
0561639 08C0009 France ⤷  Sign Up PRODUCT NAME: ANIDULAFUNGINE; REGISTRATION NO/DATE: EU/1/07/416/001 20070920
0561639 91406 Luxembourg ⤷  Sign Up 91406, EXPIRES: 20180318
0561639 SPC/GB08/016 United Kingdom ⤷  Sign Up PRODUCT NAME: ANIDULAFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/416/001 20070920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.